Striking a Balance: Exploring the Role of SGLT Inhibitors in the Treatment of Type 1 Diabetes

Release date: May 10, 2019
Expiration date: May 10, 2020
Estimated time to complete activity: 0.50 hour(s)

 

FACULTY

John Buse, MD, PhD
Verne S. Caviness Distinguished Professor
Director, Diabetes Center
Chief, Division of Endocrinology
Executive Associate Dean, Clinical Research
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Anne L. Peters, MD
Director, USC Clinical Diabetes Program
Professor of Clinical Medicine
University of Southern California
Los Angeles, California

PROGRAM OVERVIEW

Insulin is the staple of therapy in patients with T1DM; however, sodium-glucose cotransporter (SGLT) inhibitors have been investigated as a potential adjunct therapy to improve glycemic outcomes while minimizing adverse events in these patients. To be best prepared to achieve glycemic goals in patients with T1DM, HCPs must be kept up-to-date on new evidence from the medical literature and clinical practice, including the relationship between glycemic control and micro/macrovascular complications, strategies for achieving effective glycemic control, and recent data on the use of SGLT inhibitors alongside insulin to improve outcomes.

TARGET AUDIENCE

This program is intended for endocrinologists and healthcare providers that manage patients with T1DM.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be better able to:

  • Explain the relationship between glycemic control and micro/macrovascular complications in patients with T1DM
  • Apply current evidence-based strategies to achieve glycemic control while minimizing common side effects of insulin therapy
  • Discuss the evolving role of SGLT inhibitors with insulin in patients with T1DM
DIRECTIONS TO THE LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of May 10, 2019 through May 10, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education designates this enduring material for a maximum of 0.50 AMA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

John Buse, MD, PhD
Consultant: Neurimmune AG
Research: Novo Nordisk, Sanofi, vTv Therapeutics
Ownership Interest: Mellitus Health, PhaseBio, Stability Health

Anne L. Peters, MD
Consultant: Abbott Diabetes Care, Becton Dickinson, Boehringer Ingelheim, Eli Lilly and Company, Lexicon, Livongo, Medscape, Merck, Novo Nordisk, OptumHealth, Sanofi
Speakers’ Bureaus: Novo Nordisk, Sanofi
Research: AstraZeneca, Dexcom, Mannkind
Stock Options: Mellitus Health, Omada Health, Stability Health

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

PROVIDER STATEMENT

This CME activity is provided by Integrity Continuing Education.

SUPPORTER ACKNOWLEDGMENT

This activity is supported by an independent education grant from AstraZeneca Pharmaceuticals LP.

Continue to Pretest